US 12,168,803 B2
Compositions and methods for screening and diagnosis of prostate cancer
Christopher Sweeney, Waban, MA (US); Philip Kantoff, New York, NY (US); Gwo-Shu Mary Lee, Newton, MA (US); and Kazumasa Komura, New York, NY (US)
Assigned to DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US)
Filed by DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US)
Filed on Jun. 17, 2021, as Appl. No. 17/350,833.
Application 17/350,833 is a division of application No. 16/066,876, granted, now 11,066,708, previously published as PCT/US2016/069383, filed on Dec. 30, 2016.
Claims priority of provisional application 62/273,946, filed on Dec. 31, 2015.
Prior Publication US 2022/0042105 A1, Feb. 10, 2022
Int. Cl. C12Q 1/68 (2018.01); A61K 31/337 (2006.01); A61K 31/4166 (2006.01); A61P 35/00 (2006.01); C12N 5/09 (2010.01); C12Q 1/6806 (2018.01); C12Q 1/686 (2018.01); C12Q 1/6886 (2018.01); G01N 33/574 (2006.01)
CPC C12Q 1/6886 (2013.01) [A61K 31/337 (2013.01); A61K 31/4166 (2013.01); A61P 35/00 (2018.01); C12N 5/0693 (2013.01); C12Q 1/6806 (2013.01); C12Q 1/686 (2013.01); G01N 33/57434 (2013.01); C12Q 2600/112 (2013.01); C12Q 2600/118 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01); C12Q 2600/166 (2013.01); G01N 2800/52 (2013.01)] 19 Claims
 
1. A method of treating prostate cancer in a subject in need thereof, comprising:
(a) comparing a protein expression level of KDM5D in a sample from the subject to a protein expression level of KDM5D in a control sample, and
(b) when the protein expression level of KDM5D in the sample from the subject is the same as or higher than the protein expression level of KDM5D in the control sample, then administering a taxane without androgen deprivation therapy (ADT) to the subject or administering ADT without a taxane,
and when the protein expression level of KDM5D in the sample from the subject is lower than the protein expression level in the control sample, administering taxane and an ADT to the subject.